{
    "organizations": [],
    "uuid": "38f162916aa7681e5e4679eb37e1792ee9ceb09d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-precigen-announces-first-patient-d/brief-precigen-announces-first-patient-dosed-in-phase-1-clinical-study-of-inxn-4001-idUSFWN1SS0HW",
    "ord_in_thread": 0,
    "title": "BRIEF-Precigen Announces First Patient Dosed In Phase 1 Clinical Study Of INXN-4001",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Intrexon Corp:\n* PRECIGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL STUDY OF INXN-4001 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T20:18:00.000+03:00",
    "crawled": "2018-05-22T19:16:39.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "intrexon",
        "corp",
        "precigen",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "clinical",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}